Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ting Deng
Observed name:
Deng, Ting
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
ORCID:
0000-0003-4552-8039
Observed ORCID:
0000-0003-4552-8039
OpenAlex ID:
A5061337305
Interpretable multi-modal artificial intelligence model for predicting gastric cancer response to neoadjuvant chemotherapy
2024
·
Peng Gao
, Qiong Xiao
, et al.
·
Cell Reports Medicine
·
44
The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer
2023
·
Yuchong Yang
, Yao Lu
, et al.
·
BMC Cancer
·
31
PDF
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025
·
Geoffrey Ku
, Lin Shen
, et al.
·
Clinical Cancer Research
·
30
PDF
Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial
2025
·
Rui Liu
, Zhi Ji
, et al.
·
Nature Communications
·
29
PDF
Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022
2023
·
Le Zhang
, Rui Liu
, et al.
·
Cancer Innovation
·
16
PDF
Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study
2024
·
Tao Ning
, Danyang Li
, et al.
·
Cancer
·
14
Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study
2023
·
Ting Deng
, Zhigang Liu
, et al.
·
Therapeutic Advances in Medical Oncology
·
14
PDF
Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study
2024
·
Ting Deng
, Feixue Wang
, et al.
·
Cancer Immunology Immunotherapy
·
11
The mRNA export pathway licenses viral mimicry response and antitumor immunity by actively exporting nuclear retroelement transcripts
2025
·
Xiaoqiang Wang
, Jiaxing Jin
, et al.
·
Science Translational Medicine
·
9
Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study
2024
·
Jingjing Duan
, Lila Zhu
, et al.
·
BMC Cancer
·
9
PDF
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers
2025
·
Sara Hurvitz
, Matteo Simonelli
, et al.
·
Future Oncology
·
7
PDF
Feasibility and Safety of PD-1 Blockades Among Elderly Patients with Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Study
2024
·
Ming Bai
, Wei-Xue Wang
, et al.
·
Drug Design Development and Therapy
·
5
PDF
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
2026
·
Zhi Peng
, Tianshu Liu
, et al.
·
Nature Medicine
·
4
Phase I/IIa study of DN022150, a novel selective noncovalent small molecule KRAS G12D inhibitor in patients with advanced KRAS G12D–mutant solid tumors.
2026
·
Yiyi Yu
, Tianshu Liu
, et al.
·
Journal of Clinical Oncology
·
4
Third-line treatment patterns and clinical outcomes for metastatic colorectal cancer: a retrospective real-world study
2023
·
Ting Deng
, Jingjing Duan
, et al.
·
Therapeutic Advances in Chronic Disease
·
4
A single center phase 2 study of anti-PD-1 antibody plus bevacizumab and FOLFIRI as second-line treatment for patients with MSI-H metastatic colorectal cancer.
2022
·
Hongli Li
, Tao Ning
, et al.
·
Journal of Clinical Oncology
·
4
Efficacy and safety of XNW27011, a Claudin-18.2 targeted (CLDN18.2) ADC, in advanced pancreatic ductal adenocarcinoma: A phase 2 study.
2026
·
Linlin Wang
, Tianshu Liu
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma
2024
·
Yuchong Yang
, Hui Tan
, et al.
·
BMC Cancer
·
3
PDF
Toripalimab combined with fluorouracil, leucovorin calcium, oxaliplatin and irinotecan (FOLFIRINOX) regimen or combined with oxaliplatin and tegafur (SOX) regimen in perioperative treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma (G/GEJ): An open-label, randomized, phase II study.
2023
·
Rui Liu
, Zhi Ji
, et al.
·
Journal of Clinical Oncology
·
3
[Protective effect of TAK242 blocking Toll-like receptor 4 pathway on septic myocardial injury and cardiac dysfunction].
2021
·
Ziyang Liu
, Kai Yang
, et al.
·
PubMed
·
3
Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (Chemo)/trastuzumab (Tra) for first-line (1L) HER2-expressing locally advanced or metastatic (la/m) gastric cancer (GC): Updated results from the RC48-C027 trial.
2026
·
Zhi Peng
, Changzheng Li
, et al.
·
Journal of Clinical Oncology
·
2
Chinese consensus on first-line precision therapy for advanced gastric cancer
2026
·
Xiaotian Zhang
, Weiqi Sheng
, et al.
·
The Innovation
·
2
The combination of anti-PD-1 antibodies, trastuzumab and chemotherapy may improve the outcome of some patients with HER2-positive alpha-fetoprotein-producing gastric cancer: a retrospective real-world analysis from a single center
2025
·
Shaohua Ge
, Feixue Wang
, et al.
·
BMC Cancer
·
2
PDF
[Corrigendum] miR‑370 regulates cell proliferation and migration by targeting EGFR in gastric cancer
2022
·
Tao Ning
, Haiyang Zhang
, et al.
·
Oncology Reports
·
2
PDF
Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal carcinoma (mGEAC): First results from a phase Ib/II dose-escalation trial.
2026
·
Izuma Nakayama
, Bernard Gaston Doger de Spéville
, et al.
·
Journal of Clinical Oncology
·
1
Show more works
View as search
Works count:
51
Citation count:
257
H-index:
9
I10-index:
8
Year
Topic
Type